Zydus has entered into a partnership with Agenus to bring next-generation immunotherapy platform, BOT and BAL, to India. This innovative therapy aims to boost and maintain the immune system’s ability to target tumour cells effectively. The collaboration between Zydus and Agenus signifies a significant step towards advancing cancer treatment options in the region, offering hope […]
Tag: Agenus
Zydus Acquires Agenus’ US Biologics Facilities for Expansion
In a strategic move that will indubitably send ripples through the biologics sector, Zydus Lifesciences has acquired two sophisticated biologics manufacturing facilities in the heart of California’s biotech hub, from renowned immuno-oncology company Agenus Inc. This acquisition marks a significant step forward for Zydus, positioning the company to not just dip its toes, but dive […]
Zydus Lifesciences Acquires Agenus Cancer Immunotherapy Rights
Zydus Lifesciences, a reputed name in the Indian biotech industry, has made a strategic move, securing the rights for Agenus’ innovative cancer immunotherapy BOT/BAL in India and Sri Lanka. This partnership, which aligns perfectly with Zydus’ vision for advancing biologics and addressing high-unmet medical needs, is poised to significantly transform the oncology landscape in the […]
Zydus Acquisition of Agenus Facilities in California
In a significant move that promises to reshape the American biotech landscape, Zydus is poised to acquire Agenus’ facilities in California. This acquisition is a keen strategic maneuver that is set to fortify Zydus’ foothold in the US biotech market, and will propel the company into a promising realm of expanded research and development capabilities. […]
Agenus Advancing BOT/BAL Partnership for Cancer Treatment
Agenus Inc. and Zydus Lifesciences Ltd are fanning the flames of a promising partnership, a beacon of hope for patients battling solid tumors worldwide. The collaboration aims to accelerate the advancement of BOT/BAL, an innovative potential treatment that has the biotech industry buzzing with anticipation. This partnership is not just a powerful testament to the […]
Agenus Upgraded Due to Zydus Deal Reducing Cash Burden
Title: Agenus’ Strategic Cost-Cutting and Zydus Deal: A Stepping Stone to Biotech Innovation and Growth Agenus, a forerunner in the biotech industry, recently unveiled an ambitious plan to substantially minimize its annual operating cash burn to less than $50 million by the second half of 2025. The company’s strategic realignment is underpinned by a series […]
Zydus Lifesciences Enters Global Biologics CDMO Sector
Zydus Lifesciences is poised to make a significant entry into the global biologics CDMO business through the acquisition of US-based Genus Inc. This move aligns with Zydus’ strategic vision in biologics and their commitment to developing innovative solutions for unmet medical needs, particularly in the field of immuno-oncology. The collaboration with Agenus, a key player […]
Agenus, Zydus Lifesciences Collaborate to Advance Biologics Manufacturing
Agenus and Zydus Lifesciences have entered a $141M strategic collaboration to advance their BOT/BAL programs and expand Zydus’ biologics manufacturing in the US. Forward-looking statements in this press release highlight the companies’ botensilimab and balstilimab programs, expected regulatory timelines, and filings. It is crucial to note that these statements are subject to risks and uncertainties […]
Zydus Strengthens Biologics Presence Through Agenus Deal
Zydus has solidified its position in the global biologics market through the acquisition of Agenus, which includes biologics manufacturing sites in Emeryville and Berkeley, California. The deal involves an upfront payment of $75 million, with an additional $50 million in milestone-based payments over three years. These facilities will support Zydus’ new biologics CDMO business, catering […]
